Adjunctive radiofrequency ablation of metastatic neuroendocrine cancer to the liver complements surgical resection

HPB

Volumn 15, Issue 3, 2013, Pages 190-195

  Taner, Timucin ^a   Atwell, Thomas D ^a   Zhang, Lizhi ^a   Oberg, Trynda N ^a   Harmsen, William S ^a   Slettedahl, Seth W ^a   Kendrick, Michael L ^a   Nagorney, David M ^a   Que, Florencia G ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABSCESS; ADULT; AGE; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; FEMALE; GENDER; HUMAN; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE CANCER; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; RADIOFREQUENCY ABLATION;

EID: 84873410521     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2012.00528.x     Document Type: Article

References (20)

1. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, et al,. (2000) Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190: 432-445.
2. Modlin IM, Lye KD, Kidd M,. (2003) A 5-decade analysis of 13 715 carcinoid tumors. Cancer 97: 934-959.
3. Bajetta E, Ferrari L, Procopio G, Catena L, Ferrario E, Martinetti A, et al,. (2002) Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol 13: 614-621.
4. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al,. (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27: 4656-4663.
5. Mayo SC, de Jong MC, Pulitano C, Clary BM, Reddy SK, Gamblin TC, et al,. (2010) Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol 17: 3129-3136.
6. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG,. (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197: 29-37.
7. Moertel CG,. (1987) Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 5: 1502-1522.
8. Gamblin TC, Christians K, Pappas SG,. (2011) Radiofrequency ablation of neuroendocrine hepatic metastasis. Surg Oncol Clin N Am 20: 273-279.
9. Mazzaglia PJ, Berber E, Milas M, Siperstein AE,. (2007) Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery 142: 10-19.
10. Eriksson J, Stalberg P, Nilsson A, Krause J, Lundberg C, Skogseid B, et al,. (2008) Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg 32: 930-938.
11. Maithel SK, Fong Y,. (2009) Hepatic ablation for neuroendocrine tumor metastases. J Surg Oncol 100: 635-638.
12. Curley SA, Izzo F, Delrio P, Ellis LM, Granchi J, Vallone P, et al,. (1999) Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg 230: 1-8.
13. Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN,. (2003) Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 226: 441-451.
14. Frilling A, Li J, Malamutmann E, Schmid KW, Bockisch A, Broelsch CE,. (2009) Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg 96: 175-184.
15. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S,. (2010) The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 39: 707-712.
16. Ferrone CR, Tang LH, Tomlinson J, Gonen M, Hochwald SN, Brennan MF, et al,. (2007) Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol 25: 5609-5615.
17. Rosenau J, Bahr MJ, von Wasielewski R, Mengel M, Schmidt HH, Nashan B, et al,. (2002) Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation 73: 386-394.
18. Atwell TD, Charboneau JW, Que FG, Rubin J, Lewis BD, Nagorney DM, et al,. (2005) Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques. Cardiovasc Intervent Radiol 28: 409-421.
19. Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK,. (1995) Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 169: 36-42.
20. Mayo SC, de Jong MC, Bloomston M, Pulitano C, Clary BM, Reddy SK,. (2011) Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol 18: 3657-3665.